Drugs / TCC1727
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07371663 | Dec 2025 → Sep 2028 expected | endometrial cancer, gastric cancer, melanoma, non-small cell lung carcinoma | Beijing Tide Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05970016 | Aug 2023 → Jul 2025 overdue | — | Beijing Tide Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCC1727 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07371663 ↗ |
| Route | Oral | “administered orally once a day (QD)” NCT05970016 ↗ |